EP2913676A1 — Methods and compositions for diagnosis and prognosis of renal injury and renal failure
Assigned to Astute Medical Inc · Expires 2015-09-02 · 11y expired
What this patent protects
The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect Hepatocyte gr…
USPTO Abstract
The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect Hepatocyte growth factor and optionally one or more markers selected from the group consisting of Clusterin, Heart- type fatty acid binding protein, Interferon gamma, Interleukin- 12 subunit beta, Interleukin-16, Interleukin-2, 72 kDa type IV collagenase, Matrix metalloproteinase-9, Midkine, and Serum amyloid P-component as diagnostic and prognostic biomarkers in renal injuries.
Drugs covered by this patent
- terlipressin-acetate (Terlipressin acetate) · Novartis Pharmaceuticals
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.